Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid

Leslie Ann Mitchell; Aviva Joseph; Eli Kedar; Yechezkel Barenholz; Eitan Galun

doi:10.1016/j.vaccine.2006.04.015

Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid

Leslie Ann Mitchell^*, Aviva Joseph, Eli Kedar, Yechezkel Barenholz, Eitan Galun

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal-oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of killed HAV with synthetic oligodeoxynucleotides (ODNs) containing CpG sequences, and a novel polycationic sphingolipid (CCS)/cholesterol liposomal delivery system, markedly enhances the HAV-specific antibody response at the intestinal interface, particularly when delivered intrarectally or intranasally, to Balb/c mice at low HAV doses. A mucosally delivered, antigen-sparing HAV vaccine that is easily administered without specialized equipment or personnel, is an attractive alternative for facilitating mass immunization in hepatitis A outbreaks.

Original language	English
Pages (from-to)	5300-5310
Number of pages	11
Journal	Vaccine
Volume	24
Issue number	25
DOIs	https://doi.org/10.1016/j.vaccine.2006.04.015
State	Published - 19 Jun 2006

Bibliographical note

Funding Information:
This study was supported by grants from the Israeli Ministry of Science through its National Knowledge Center in Gene Therapy at Hadassah-Hebrew University Hospital in Jerusalem (EG), and by grants from the Grinspoon, Blum, and Horowitz Foundations provided to the Gene Therapy Center (EG), and by Israeli Ministry of Absorption for Immigrant Scientists (LAM).

Keywords

Cationic lipid delivery system
CpG motifs
Hepatitis A
Synthetic ODN adjuvants

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2006.04.015

Cite this

@article{ff0ad3d27bd74d95a4298481f3df85c9,

title = "Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid",

abstract = "Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal-oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of killed HAV with synthetic oligodeoxynucleotides (ODNs) containing CpG sequences, and a novel polycationic sphingolipid (CCS)/cholesterol liposomal delivery system, markedly enhances the HAV-specific antibody response at the intestinal interface, particularly when delivered intrarectally or intranasally, to Balb/c mice at low HAV doses. A mucosally delivered, antigen-sparing HAV vaccine that is easily administered without specialized equipment or personnel, is an attractive alternative for facilitating mass immunization in hepatitis A outbreaks.",

keywords = "Cationic lipid delivery system, CpG motifs, Hepatitis A, Synthetic ODN adjuvants",

author = "Mitchell, {Leslie Ann} and Aviva Joseph and Eli Kedar and Yechezkel Barenholz and Eitan Galun",

note = "Funding Information: This study was supported by grants from the Israeli Ministry of Science through its National Knowledge Center in Gene Therapy at Hadassah-Hebrew University Hospital in Jerusalem (EG), and by grants from the Grinspoon, Blum, and Horowitz Foundations provided to the Gene Therapy Center (EG), and by Israeli Ministry of Absorption for Immigrant Scientists (LAM).",

year = "2006",

month = jun,

day = "19",

doi = "10.1016/j.vaccine.2006.04.015",

language = "אנגלית",

volume = "24",

pages = "5300--5310",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "25",

}

TY - JOUR

T1 - Mucosal immunization against hepatitis A

T2 - Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid

AU - Mitchell, Leslie Ann

AU - Joseph, Aviva

AU - Kedar, Eli

AU - Barenholz, Yechezkel

AU - Galun, Eitan

N1 - Funding Information: This study was supported by grants from the Israeli Ministry of Science through its National Knowledge Center in Gene Therapy at Hadassah-Hebrew University Hospital in Jerusalem (EG), and by grants from the Grinspoon, Blum, and Horowitz Foundations provided to the Gene Therapy Center (EG), and by Israeli Ministry of Absorption for Immigrant Scientists (LAM).

PY - 2006/6/19

Y1 - 2006/6/19

N2 - Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal-oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of killed HAV with synthetic oligodeoxynucleotides (ODNs) containing CpG sequences, and a novel polycationic sphingolipid (CCS)/cholesterol liposomal delivery system, markedly enhances the HAV-specific antibody response at the intestinal interface, particularly when delivered intrarectally or intranasally, to Balb/c mice at low HAV doses. A mucosally delivered, antigen-sparing HAV vaccine that is easily administered without specialized equipment or personnel, is an attractive alternative for facilitating mass immunization in hepatitis A outbreaks.

AB - Hepatitis A caused by hepatitis A virus (HAV) transmitted by the fecal-oral route, results in considerable morbidity and economic loss. Mucosal immunization can be more effective than conventional injection at inducing both local and systemic immunity to HAV. Here we show that co-administration of killed HAV with synthetic oligodeoxynucleotides (ODNs) containing CpG sequences, and a novel polycationic sphingolipid (CCS)/cholesterol liposomal delivery system, markedly enhances the HAV-specific antibody response at the intestinal interface, particularly when delivered intrarectally or intranasally, to Balb/c mice at low HAV doses. A mucosally delivered, antigen-sparing HAV vaccine that is easily administered without specialized equipment or personnel, is an attractive alternative for facilitating mass immunization in hepatitis A outbreaks.

KW - Cationic lipid delivery system

KW - CpG motifs

KW - Hepatitis A

KW - Synthetic ODN adjuvants

UR - http://www.scopus.com/inward/record.url?scp=33744783405&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.04.015

DO - 10.1016/j.vaccine.2006.04.015

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???

C2 - 16714070

AN - SCOPUS:33744783405

SN - 0264-410X

VL - 24

SP - 5300

EP - 5310

JO - Vaccine

JF - Vaccine

IS - 25

ER -

Mucosal immunization against hepatitis A: Antibody responses are enhanced by co-administration of synthetic oligodeoxynucleotides and a novel cationic lipid

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this